top of page
![BioAtlantis will bring Digestica to the market in 2023 to help humans prime the body to deal with methabolic issues](https://static.wixstatic.com/media/44a315_3379a7431b694af684b51ee20c22bf3c~mv2.jpg/v1/fill/w_980,h_359,al_c,q_80,usm_0.66_1.00_0.01,enc_avif,quality_auto/44a315_3379a7431b694af684b51ee20c22bf3c~mv2.jpg)
Human
BioAtlantis is developing nutraceutical compositions targeting immunological, metabolic and stress-related conditions in humans. This technology is based on the use of natural compounds that modulate biological processes in humans, with efficacy proven in a diverse range of cohorts. Our flagship nutraceutical, Digestica®, is based on a unique composition that works in vivo to address immunological and metabolic abnormalities.
bottom of page